talactoferrin alfa has been researched along with Disease Exacerbation in 1 studies
talactoferrin alfa: recombinant human lactoferrin, an oral drug for treatment of refractory solid tumors; in Phase I trial 5/2006
| Excerpt | Relevance | Reference |
|---|---|---|
| " Oral TLF or placebo was administered for a maximum of three 14-week cycles with dosing for 12 consecutive weeks followed by 2 weeks off." | 2.76 | Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. ( Advani, SH; Bapna, A; Digumarti, R; Ismail, PM; Madhavan, J; Malik, R; Nag, S; Parikh, PM; Patil, S; Sekhon, JS; Vaid, A; Varadhachary, A; Wang, Y; Zhu, J, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Parikh, PM | 1 |
| Vaid, A | 1 |
| Advani, SH | 1 |
| Digumarti, R | 1 |
| Madhavan, J | 1 |
| Nag, S | 1 |
| Bapna, A | 1 |
| Sekhon, JS | 1 |
| Patil, S | 1 |
| Ismail, PM | 1 |
| Wang, Y | 1 |
| Varadhachary, A | 1 |
| Zhu, J | 1 |
| Malik, R | 1 |
1 trial available for talactoferrin alfa and Disease Exacerbation
| Article | Year |
|---|---|
Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2011 |